DE60043870D1 - Auf bovinem Immundefizienvirus (BIV) basierende Vektoren - Google Patents

Auf bovinem Immundefizienvirus (BIV) basierende Vektoren

Info

Publication number: DE60043870D1
Authority: DE; Germany
Prior art keywords: biv; gene; vectors; operably linked; packaging
Prior art date: 1999-12-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60043870T

Other languages

English (en)

Inventor

Tianci Luo

Robert David Berkowitz

Michael Kaleko

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis AG

Original Assignee

Novartis AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-14

Filing date

2000-12-13

Publication date

2010-04-01

2000-12-12 Priority claimed from US09/734,836 external-priority patent/US6864085B2/en

2000-12-13 Application filed by Novartis AG filed Critical Novartis AG

2010-04-01 Application granted granted Critical

2010-04-01 Publication of DE60043870D1 publication Critical patent/DE60043870D1/de

2020-12-14 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15051—Methods of production or purification of viral material
- C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/46—Vector systems having a special element relevant for transcription elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Virology (AREA)
General Chemical & Material Sciences (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Physics & Mathematics (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Plant Pathology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

DE60043870T 1999-12-14 2000-12-13 Auf bovinem Immundefizienvirus (BIV) basierende Vektoren Expired - Lifetime DE60043870D1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US46446099A	1999-12-14	1999-12-14
US24949200P	2000-11-17	2000-11-17
US09/734,836 US6864085B2 (en)	1999-12-14	2000-12-12	Bovine immunodeficiency virus (BIV) based vectors

Publications (1)

Publication Number	Publication Date
DE60043870D1 true DE60043870D1 (de)	2010-04-01

Family

ID=27400217

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DE60043870T Expired - Lifetime DE60043870D1 (de)	1999-12-14	2000-12-13	Auf bovinem Immundefizienvirus (BIV) basierende Vektoren
DE60033180T Expired - Lifetime DE60033180T2 (de)	1999-12-14	2000-12-13	Auf dem rinderimmunschwächevirus (biv) basierte vektoren

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DE60033180T Expired - Lifetime DE60033180T2 (de)	1999-12-14	2000-12-13	Auf dem rinderimmunschwächevirus (biv) basierte vektoren

Country Status (10)

Country	Link
EP (2)	EP1852511B1 (de)
JP (3)	JP2003517312A (de)
AT (2)	ATE352636T1 (de)
AU (1)	AU778110B2 (de)
CA (1)	CA2392221C (de)
DE (2)	DE60043870D1 (de)
ES (2)	ES2281369T3 (de)
IL (2)	IL149704A0 (de)
NZ (1)	NZ519034A (de)
WO (1)	WO2001044458A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2170622B1 (es)	1999-12-03	2004-05-16	Consejo Superior De Investigaciones Cientificas	Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
JP2003517312A (ja) *	1999-12-14	2003-05-27	ノバルティスアクチエンゲゼルシャフト	ウシ免疫不全ウイルス由来ベクター
US7575924B2 (en)	2000-11-13	2009-08-18	Research Development Foundation	Methods and compositions relating to improved lentiviral vectors and their applications
US7070993B2 (en)	2001-03-13	2006-07-04	Novartis Ag	Lentiviral packaging constructs
ATE527347T1 (de)	2001-08-02	2011-10-15	Inst Clayton De La Rech	Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen
CN1606456A (zh)	2001-10-02	2005-04-13	克雷顿研究院	限制性表达慢病毒载体
ES2208051B1 (es) *	2002-01-24	2005-08-16	Consejo Sup. Investig. Cientificas	Secuencia de acido nucleico que comprende la señal de encapsidacion del rna de un coronavirus del grupo 1 y sus aplicaciones.
AU2003225544A1 (en) *	2002-02-04	2003-09-02	Novartis Ag	Recombinant bovine immunodeficiency virus based gene transfer system
GB2450688A (en) *	2005-05-11	2009-01-07	Viragen Inc	Ovalbumin promoter constructs for retroviral vectors
WO2015117027A1 (en) *	2014-01-30	2015-08-06	Children's Hospital Medical Center	An improved fetal hemoglobin for genetic correction of sickle cell disease
GB202114532D0 (en) *	2021-10-12	2021-11-24	Oxford Biomedica Ltd	Lentiviral Vectors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5380830A (en) *	1989-09-18	1995-01-10	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Molecular clones of bovine immunodeficiency-like virus
US6013516A (en) *	1995-10-06	2000-01-11	The Salk Institute For Biological Studies	Vector and method of use for nucleic acid delivery to non-dividing cells
FR2768743B1 (fr)	1997-09-23	2001-09-14	Bio Merieux	Procede de lyse de micro-organisme
EP1017797B1 (de) *	1997-09-24	2005-06-22	The Regents Of The University Of California	Nicht-primaten lentivirale vektoren und verpackungssysteme
JP4612950B2 (ja) *	1998-05-22	2011-01-12	オックスフォードバイオメディカ（ユーケー）リミテッド	レトロウイルス送達システム
JP2003517312A (ja) *	1999-12-14	2003-05-27	ノバルティスアクチエンゲゼルシャフト	ウシ免疫不全ウイルス由来ベクター

2000
- 2000-12-13 JP JP2001545535A patent/JP2003517312A/ja active Pending
- 2000-12-13 EP EP07001113A patent/EP1852511B1/de not_active Expired - Lifetime
- 2000-12-13 EP EP00986343A patent/EP1238092B1/de not_active Expired - Lifetime
- 2000-12-13 AT AT00986343T patent/ATE352636T1/de active
- 2000-12-13 WO PCT/US2000/033725 patent/WO2001044458A2/en active IP Right Grant
- 2000-12-13 DE DE60043870T patent/DE60043870D1/de not_active Expired - Lifetime
- 2000-12-13 ES ES00986343T patent/ES2281369T3/es not_active Expired - Lifetime
- 2000-12-13 NZ NZ519034A patent/NZ519034A/en not_active IP Right Cessation
- 2000-12-13 ES ES07001113T patent/ES2340073T3/es not_active Expired - Lifetime
- 2000-12-13 IL IL14970400A patent/IL149704A0/xx unknown
- 2000-12-13 AU AU22598/01A patent/AU778110B2/en not_active Ceased
- 2000-12-13 DE DE60033180T patent/DE60033180T2/de not_active Expired - Lifetime
- 2000-12-13 CA CA2392221A patent/CA2392221C/en not_active Expired - Fee Related
- 2000-12-13 AT AT07001113T patent/ATE458062T1/de not_active IP Right Cessation
2002
- 2002-05-16 IL IL149704A patent/IL149704A/en not_active IP Right Cessation
2010
- 2010-02-26 JP JP2010043354A patent/JP2010166919A/ja active Pending
2013
- 2013-12-24 JP JP2013265269A patent/JP2014110789A/ja active Pending

Also Published As

Publication number	Publication date
WO2001044458A3 (en)	2001-11-29
EP1238092B1 (de)	2007-01-24
JP2003517312A (ja)	2003-05-27
NZ519034A (en)	2005-02-25
AU2259801A (en)	2001-06-25
EP1852511B1 (de)	2010-02-17
JP2010166919A (ja)	2010-08-05
ATE458062T1 (de)	2010-03-15
CA2392221A1 (en)	2001-06-21
ES2340073T3 (es)	2010-05-28
DE60033180T2 (de)	2007-10-25
EP1852511A1 (de)	2007-11-07
ATE352636T1 (de)	2007-02-15
DE60033180D1 (de)	2007-03-15
IL149704A (en)	2013-02-28
JP2014110789A (ja)	2014-06-19
ES2281369T3 (es)	2007-10-01
IL149704A0 (en)	2002-11-10
AU778110B2 (en)	2004-11-18
EP1238092A2 (de)	2002-09-11
CA2392221C (en)	2012-01-31
WO2001044458A2 (en)	2001-06-21

Publication	Publication Date	Title
Garcia-Sastre et al.	1994	Use of a mammalian internal ribosomal entry site element for expression of a foreign protein by a transfectant influenza virus
Jeffers et al.	2002	Covalent modifications of the ebola virus glycoprotein
RU2733832C1 (ru)	2020-10-07	Искусственный ген Stbl_RBD_TrM_SC2, кодирующий бицистронную структуру, образованную последовательностями рецепторсвязывающего домена гликопротеина S коронавируса SARS-CoV-2, трансмембранного региона, P2A-пептида и гликопротеина G VSV, рекомбинантная плазмида pStem-rVSV-Stbl_RBD_TrM_SC2, обеспечивающая экспрессию искусственного гена, и рекомбинантный штамм вируса везикулярного стоматита rVSV-Stbl_RBD_TrM_SC2, используемый для создания вакцины против коронавируса SARS-CoV-2
Pinter et al.	1997	Localization of the labile disulfide bond between SU and TM of the murine leukemia virus envelope protein complex to a highly conserved CWLC motif in SU that resembles the active-site sequence of thiol-disulfide exchange enzymes
Binley et al.	2002	Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins
Hahn et al.	1992	Infectious Sindbis virus transient expression vectors for studying antigen processing and presentation.
Richins et al.	1987	Sequence of figwort mosaic virus DNA (caulimovirus group)
ATE291632T1 (de)	2005-04-15	Auf lentivirus basierende gentransfer-vektoren
ATE458062T1 (de)	2010-03-15	Auf bovinem immundefizienvirus (biv) basierende vektoren
DK1792997T3 (da)	2012-01-30	Lentiviral triplex DNA og vektorer og rekombinante celler indeholdende lentiviralt triplex DNA
JP2005502355A5 (de)	2008-11-27
SG55158A1 (en)	1998-12-21	Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
Dash et al.	1994	Deletion of a single N-linked glycosylation site from the transmembrane envelope protein of human immunodeficiency virus type 1 stops cleavage and transport of gp160 preventing env-mediated fusion
Schwartz et al.	1997	Distinct functions and requirements for the Cys-His boxes of the human immunodeficiency virus type 1 nucleocapsid protein during RNA encapsidation and replication
Bobkova et al.	2002	Identification of R-peptides in envelope proteins of C-type retroviruses
DE69631480D1 (de)	2004-03-11	Helfersystem zur wirkungssteigerung der aav-vektorproduktion
Beyer et al.	2001	Recombinant expression of lymphocytic choriomeningitis virus strain WE glycoproteins: a single amino acid makes the difference
JP2004524805A5 (de)	2011-10-13
Gaudin et al.	1999	Soluble ectodomain of rabies virus glycoprotein expressed in eukaryotic cells folds in a monomeric conformation that is antigenically distinct from the native state of the complete, membrane-anchored glycoprotein
Du et al.	2010	Efficient replication and generation of recombinant bovine adenovirus‐3 in nonbovine cotton rat lung cells expressing I‐SceI endonuclease
WO2022272296A3 (en)	2023-03-02	Adeno-associated virus packaging systems
Kobayashi et al.	2000	Translation initiation of a bicistronic mRNA of Borna disease virus: a 16-kDa phosphoprotein is initiated at an internal start codon
Spannaus et al.	2012	The prototype foamy virus protease is active independently of the integrase domain
Nakayama et al.	2001	Leucine at position 278 of the AIK-C measles virus vaccine strain fusion protein is responsible for reduced syncytium formation
Alkhatib et al.	1994	Characterization of a cleavage mutant of the measles virus fusion protein defective in syncytium formation

Legal Events

Date	Code	Title	Description
2011-03-10	8364	No opposition during term of opposition